Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.200
+0.005 (2.62%)
At close: Apr 28, 2026

Northwest Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
326358364822830663
Upgrade
Market Cap Growth
19.87%-1.53%-55.72%-1.00%25.14%-47.13%
Upgrade
Enterprise Value
400444435881865686
Upgrade
Last Close Price
0.200.230.270.700.780.70
Upgrade
PE Ratio
-----3.70
Upgrade
PS Ratio
236.46260.08263.35425.38493.23660.04
Upgrade
PB Ratio
-6.85-7.53-4.61-17.47-7.90-5.35
Upgrade
EV/Sales Ratio
290.52322.41314.92455.93513.96682.10
Upgrade
Debt / Equity Ratio
-1.36-1.36-0.85-0.97-0.25-0.31
Upgrade
Net Debt / Equity Ratio
-1.30-1.30-0.83-0.92-0.18-0.18
Upgrade
Net Debt / EBITDA Ratio
-1.07-1.07-1.01-0.80-0.29-0.43
Upgrade
Net Debt / FCF Ratio
-1.33-1.33-1.12-0.76-0.35-0.51
Upgrade
Asset Turnover
0.030.030.050.070.050.03
Upgrade
Quick Ratio
0.030.030.030.050.060.11
Upgrade
Current Ratio
0.060.060.060.090.080.13
Upgrade
Return on Assets (ROA)
-69.33%-69.33%-152.28%-117.23%-117.48%-90.17%
Upgrade
Return on Capital Employed (ROCE)
575.50%575.50%160.10%320.10%71.00%56.30%
Upgrade
Earnings Yield
-18.87%-16.79%-23.02%-7.62%-12.65%27.00%
Upgrade
FCF Yield
-14.20%-12.91%-15.95%-6.94%-6.71%-6.68%
Upgrade
Buyback Yield / Dilution
-17.26%-17.26%-10.99%-10.17%-0.79%-38.99%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.